The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Great. Yes. Thank you, Adam, for that presentation. (Conference Instructions)
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
APRIL 19, 2023 / 12:00PM, ZELA.CO - Zealand Pharma A/S at Needham Healthcare Conference (Virtual)
I'll start off with a few questions from myself, Adam. Just curious, in terms of the SBS program, can you detail the type of data or the data that you
need to still collect prior to the NDA submission?
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Got it. In terms of the SBS market, it's interesting, you mentioned the approved drug Gattex, and I believe you could probably provide the latest
sales figures for Gattex. I think it's north of $500 million at this point. But it's an interesting dynamic in the sense that it is an established market
given Gattex is available, but yet there are many drawbacks and flaws of Gattex.
Just curious what your thoughts are on what the market potential is if you had a more convenient option such as glepaglutide, number one, what
do you think the market could be? And then the second question is on sort of competitive, the competitive landscape. There's another late-stage
program out there. And so I guess my question is, what do you think there's room for more than one player? Maybe the market's bigger than what
it currently is. And what's it going to take to be, to win the day or be the market leader? Sorry, I jammed a lot of questions in there, but I want to
hear your thoughts.
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Great. Well, very helpful. Thank you, Adam, for the -- to you and the rest of the Zealand team for the presentation and participating in the Q&A
session. We're getting up to time. So I want to thank everyone on the webcast for joining. Have a good day and a good rest of the conference.
|
